6th Annual Conference of the Molecular Pathology Association of India (MPAI)
Scheduled For: Friday, February 10th, 2017 View all Events
|Date:||February 10-11, 2017|
Integrating Cancer Genomics and Pathology in Clinical Service to Assist in Better Treatment Regimens for Oncology Patients – Case Studies
Kishor Bhatia, Kamala Maddali, Anna Israyelyan, Rita Shaknovich, Rob, Fannon, Narasimha Marella, Mandhar Kulkarni and Rama Modali.
The rapid gain of knowledge in understanding the molecular underpinnings of cancer has provided novel tools, technologies, assays, and biomarkers allowing pathologists to play a central role in cancer theranostics. The integration of novel analytic technologies with traditional histopathology and genomics is becoming critical to precision medicine. The premise of obtaining and leveraging broad clinical and genomic data in guiding tailored cancer treatments for individual patients is made possible only by the accessibility to molecular pathology services. Such services are also crucial and relevant to India, since adaptation of cutting edge molecular diagnosis helps choose between treatment choices that would differ in their effectiveness and cost between individual patients. The likelihood of choosing suboptimal therapy is reduced, thereby diminishing both morbidity and the total cost of the treatment. We present a spectrum of cases where integration of such technologies has allowed a more precise determination of tumor characteristics to guide treatment choices. In this presentation, we will provide examples of leveraging molecular diagnostic assays that are useful in colorectal cancer, lung cancer, and breast cancer, as well as assays that help guide eligibility for novel immunotherapeutic modalities. In addition, we will provide examples of noninvasive technologies available for monitoring tumor response. These examples will illustrate how the rapid adaptation and validation of diagnostic assays reported by clinical laboratories substantially expands the role of pathologists in interpreting the molecular and histopathological features for oncologists.